WASHINGTON — The libertarian think tank behind the federal “right-to-try” law is back at it again.
Its new legislation, which became law in Arizona on Monday, is meant to speed patients’ access to bespoke treatments that target issues with patients’ own genomes. It focuses on more experimental drugs than the first right-to-try laws, which let dying patients access drugs that had cleared early clinical trials without the blessing of the Food and Drug Administration.
The think tank behind the bill, the Goldwater Institute, is planning to push similar legislation in other states and eventually advocate for federal legislation, the same way it did with the original right-to-try effort, according to Naomi Lopez-Bauman, the organization’s director of health care policy. President Trump signed the national right-to-try bill in 2018 after 40 states enacted their own laws.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect